Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Patient enrollment complete in phase III trial of beraprost for intermittent claudication

Feb. 23, 2001

Noval anticlotting agents reported in recent patent by Novo Nordisk

Feb. 22, 2001

TOPAS trial evaluates different doses of certoparin in acute ischemic stroke patients

Feb. 16, 2001

Joint research at Ortho-McNeil and Cor leads to new peptoid/peptidomimetic PAR-1 antagonists

Feb. 16, 2001

Takeda claims potent new factor Xa inhibitors

Feb. 15, 2001

Thrombin inhibitors with high selectivity designed at ADIR

Feb. 14, 2001

Avigen/Bayer hemophilia B collaboration becomes effective

Feb. 13, 2001

Genzyme Transgenics updates rhATIII development status

Feb. 13, 2001

Sanofi Synthelabo/Organon pentasaccharide can be reversed only by Neutralase

Feb. 13, 2001

Peptide inhibitors of alphavbeta6 integrin disclosed by Merck KGaA

Feb. 8, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...